Cyclo Therapeutics Merges with Rafael Holdings

An update from Cyclo Therapeutics ( (CYTH) ) is now available.

On March 25, 2025, Cyclo Therapeutics completed a strategic merger with Rafael Holdings, resulting in Cyclo becoming a wholly owned subsidiary of Rafael. This merger led to a change in control and the delisting of Cyclo’s common stock and warrants from Nasdaq. The merger is expected to enhance Rafael’s strategy to develop clinical-stage assets, particularly focusing on the TransportNPC™ Phase 3 trial for Trappsol® Cyclo™ in treating Niemann-Pick Disease Type C1. The merger is seen as a significant step forward in addressing unmet medical needs and leveraging resources to advance clinical trials.

More about Cyclo Therapeutics

Cyclo Therapeutics, LLC is a clinical-stage biotechnology company focused on developing life-changing medicines for patients with diseases such as Niemann-Pick Disease Type C1 and Alzheimer’s disease. It is a wholly owned subsidiary of Rafael Holdings, Inc., which has interests in various clinical and early-stage pharmaceutical companies.

YTD Price Performance: 20.0%

Average Trading Volume: 1,560,646

Technical Sentiment Signal: Buy

Current Market Cap: $20.73M

For an in-depth examination of CYTH stock, go to TipRanks’ Stock Analysis page.